Beta
ManageSearchChatDiscover
16242

Doxorubicin-induced cardiotoxicity in mice; protection by silymarin

Article

Last updated: 24 Dec 2024

OverviewSimilar Items

Subjects

-

Tags

-

Abstract

Background: despite its vast utility in clinical oncology, the use of doxorubicin is limited by a potentially fatal cardiomyopathy and congestive heart failure. Free radical formation and antioxidants depletion are mechanisms proposed for this cardiomyopathy. The aim of this study is to compare the potential antioxidative protective effect of silymarin on doxorubicin-induced cardiotoxicity in experimental mice.
Materials and methods: four groups (ten animals in each group) of experimental mice were used as follows: Group 1, mice received only saline (intraperitoneally) and served as a negative control group; Group 2, mice received doxorubicin (intraperitoneally, 5 mg/kg body weight) in three equal injections over a period of two weeks for a cumulative dose of 15 mg/kg body weight; Group 3, mice orally administrated silymarin (200 mg/day/kg body weight) respectively, through an intragastric feeding tube over a period of three weeks; Group 4, mice treated orally with silymarin plus intraperitoneally doxorubicin administration with the same protocol of groups 3 and 4. Serum lactate dehydrogenase (LDH), creatine phosphokinase (CPK), aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), malondialdehyde (MDA), total nitric oxide (NO), cardiac reduced glutathione (GSH), superoxide dismutase (SOD), glutathione peroxidase (GPx) and catalase (CAT) were measured in all tested groups.
Results: doxorubicin elevated the activities of LDH, CPK, AST, ALT, MDA and NO in the cardiac tissue. Cardiac antioxidant enzymes activities SOD and CAT also increased while GPx activity was decreased. Pre-co-treatment with silymarin prevented the changes induced by doxorubicin administration. These findings demonstrate the cardio-protective effect of silymarin on cardiac antioxidant status during doxorubicin induced cardiac damage in mice.
Conclusion: silymarin could be recommended for further investigation as potentially new indication for clinical application.

DOI

10.21608/ejhm.2012.16242

Keywords

Doxorubicin, cardiotoxicity, Silymarin, Antioxidant enzymes, Oxidative Stress

Authors

First Name

Heba Abdelnasser

Last Name

Aniss

MiddleName

-

Affiliation

Department of Biochemistry, Faculty of Science (Damietta branch), Mansoura University, Egypt

Email

-

City

-

Orcid

-

First Name

Camelia

Last Name

AdLy

MiddleName

-

Affiliation

Department of Biochemistry, Faculty of Science (Damietta branch), Mansoura University, Egypt

Email

-

City

-

Orcid

-

First Name

Ashraf El Metwally

Last Name

Said

MiddleName

-

Affiliation

Department of Zoology, Faculty of Science (Damietta branch), Mansoura University, Egypt

Email

-

City

-

Orcid

-

First Name

Ibrahim Helmy

Last Name

El Sayed

MiddleName

-

Affiliation

Department of Biochemistry, Research Institute for Genetic Engineering and Biotechnology, Menofia University, Egypt.

Email

-

City

-

Orcid

-

Volume

48

Article Issue

1

Related Issue

3478

Issue Date

2012-07-01

Receive Date

2018-10-09

Publish Date

2012-07-01

Page Start

383

Page End

395

Print ISSN

1687-2002

Online ISSN

2090-7125

Article File

EJHM_Volume 48_Issue 1_Pages 383-395.pdf

PDF . 277.3kB

Link

https://ejhm.journals.ekb.eg/article_16242.html

Detail API

https://ejhm.journals.ekb.eg/service?article_code=16242

Order

5

Type

Original Article

Type Code

606

Publication Type

Journal

Publication Title

The Egyptian Journal of Hospital Medicine

Publication Link

https://ejhm.journals.ekb.eg/

MainTitle

Doxorubicin-induced cardiotoxicity in mice; protection by silymarin

Details

Type

Article

Created At

22 Jan 2023